Tirzepatide and semaglutide are the two GLP-1-class medications most men are deciding between. Both work. They do not work the same way, and the right pick for a given patient is not always the one with the bigger weight-loss number in the trial.
This is the side-by-side we wish more men had before they walked into a clinic asking for "the shot."
What is the difference between tirzepatide and semaglutide?
Semaglutide is a GLP-1 receptor agonist. It mimics one gut hormone, glucagon-like peptide-1.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. It mimics two gut hormones, GLP-1 and glucose-dependent insulinotropic polypeptide.
That single mechanistic difference (the addition of GIP) is what produces most of the downstream differences in trial outcomes, side effect profile, and the patient who fits each molecule best.
Tirzepatide vs semaglutide: side-by-side
| Variable | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Mechanism | GLP-1 agonist | GLP-1 plus GIP agonist |
| Maximum weight loss at top dose (68-72 weeks) | ~15% of body weight | ~21% of body weight |
| A1c reduction at top dose | ~1.8% | ~2.4% |
| Typical starting dose | 0.25 mg/week | 2.5 mg/week |
| Top approved dose | 2.4 mg/week | 15 mg/week |
| Nausea (any grade, trials) | ~44% | ~31% |
| Discontinuation for side effects | ~7% | ~6% |
| Visceral fat reduction | Strong | Slightly stronger in head-to-head |
| FDA approval for weight | 2021 (Wegovy) | 2023 (Zepbound) |
| Generic available | No | No |
| Compounded versions | Yes, where legal | Yes, where legal |
The headline difference is the weight number. The clinically more interesting differences are the GIP-driven ones: better insulin sensitivity, slightly cleaner body composition outcomes, and (counterintuitively) lower rates of nausea in many comparisons.
How tirzepatide works differently from semaglutide
GLP-1 alone (semaglutide) does three things: slows gastric emptying, increases insulin secretion in response to glucose, and reduces appetite signaling.
Tirzepatide does all three of those, then adds GIP agonism. GIP is the gut hormone most associated with the early-phase insulin response after a meal. Adding GIP improves the cleanliness of glucose handling and appears to favor fat-mass loss over lean-mass loss compared with GLP-1 alone in some analyses.
The mechanism translates to two consistent clinical observations:
- Tirzepatide produces more total weight loss at maximum dose.
- The composition of that loss looks slightly more favorable (more fat, less lean tissue per pound dropped), though this effect is modest and depends heavily on protocol.
Side effect profile
Both drugs share the same family of side effects. Nausea, constipation, diarrhea, reduced appetite, occasional vomiting. Severity scales with dose.
Two patterns worth knowing:
- Semaglutide has slightly higher rates of nausea in many comparisons, possibly because GLP-1 alone produces a more pronounced gastric emptying slowdown than the GLP-1 plus GIP combination.
- Tirzepatide tends to produce more dramatic appetite suppression at top dose, which some patients describe as "too much." Loss of food enjoyment is a real downside for men who like to cook and eat with their families.
We cover the GI and rarer side effects in detail in the Ozempic side effects piece. Most of what is true for semaglutide is true for tirzepatide.
Which one for which patient
There is no universal answer. The factors we weigh:
Lean toward semaglutide when:
- The goal is modest, sustainable metabolic signal, not maximum weight loss.
- The patient is metabolically healthy and wants a microdose protocol.
- Cost is a primary driver and a lower-dose semaglutide protocol is more affordable.
- The patient has already tried tirzepatide and could not tolerate the GI effects.
Lean toward tirzepatide when:
- BMI is in the 30s and the goal is substantial weight loss.
- Insulin resistance is prominent on labs (high fasting insulin, A1c above 5.8).
- Type 2 diabetes is in the picture.
- Prior semaglutide trial produced inadequate response.
- Fatty liver is on the radar (tirzepatide has the better liver fat data of the two).
How long does each take to work?
Onset is similar. Appetite shifts inside one to two weeks for both drugs. Weight movement is measurable by week four. Maximum effect comes between weeks 60 and 72, though most men do not run that long.
Tirzepatide tends to produce slightly faster early weight loss. Semaglutide tends to produce slightly more gradual, steadier loss. Neither pattern is universal.
Cost and access
Brand-name versions of both are expensive without insurance coverage. List prices around $1,000 to $1,400 per month for Wegovy or Zepbound, similar for Ozempic or Mounjaro. Insurance coverage varies dramatically by plan and indication (diabetes is more often covered than obesity alone).
Compounded versions of semaglutide and tirzepatide were widely available during the FDA shortage period that began in 2022, but the FDA declared both shortages resolved (tirzepatide in October 2024, semaglutide in February 2025). After the wind-down windows ended in spring 2025, compounded copies of either molecule are no longer permitted under the shortage exemption. Treatment in 2026 means the branded products — Ozempic and Wegovy for semaglutide, Mounjaro and Zepbound for tirzepatide.
We help patients navigate the access question as part of the metabolic program intake.
Which is safer?
The safety profiles are essentially equivalent. Both carry the same boxed warning around medullary thyroid carcinoma risk (relevant for patients with personal or family history of MTC or MEN-2). Both have signals around pancreatitis and gallbladder issues. The differences in safety between the two are smaller than the differences within each drug across different patients.
Where this lands
The "tirzepatide vs semaglutide" question gets framed online as a contest. The honest clinical framing is more boring: they are two tools with overlapping use cases and modest differences. Most men do well on either. The molecule that fits is the one whose mechanism matches the patient's metabolic signature and whose side effect profile he can live with.
If you are starting from scratch, the more useful question is not which GLP-1, but whether a GLP-1 is the right tool at all and at what dose. That is the conversation that determines outcomes more than the brand on the pen.
